Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries

• Published in: Infectious diseases of poverty Vol. 6; no. 1; p. 163
• Main Authors: Gibson, Richard M, Nickel, Gabrielle, Crawford, Michael, Kyeyune, Fred, Venner, Colin, Nankya, Immaculate, Nabulime, Eva, Ndashimye, Emmanuel, Poon, Art F Y, Salata, Robert A, Kityo, Cissy, Mugyenyi, Peter, Quiñones-Mateu, Miguel E, Arts, Eric J
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 04.12.2017; BioMed Central; BMC
• Subjects: Acquired immune deficiency syndrome; AIDS; Anti-HIV agents; Antiretroviral agents; Antiretroviral drugs; Antiretroviral treatment; Care and treatment; Dosage and administration; Drug resistance; Highly active antiretroviral therapy; HIV; HIV patients; Human immunodeficiency virus; Mutation; Protease inhibitors; Uganda; Uganda; Drug resistance; Uganda; Antiretroviral treatment
• ISSN: 2049-9957; 2095-5162; 2049-9957
• DOI: 10.1186/s40249-017-0377-0

Thymidine analogs, namely AZT (Zidovudine or Retrovir™) and d4T (Stavudine or Zerit™) are antiretroviral drugs still employed in over 75% of first line combination antiretroviral therapy (cART) in Kampala, Uganda despite aversion to prescribing these drugs for cART in high income countries due in part to adverse events. For this study, we explored how the continued use of these thymidine analogs in cART could impact emergence of drug resistance and impact on future treatment success in Uganda, a low-income country. We examined the drug resistance genotypes by Sanger sequencing of 262 HIV-infected patients failing a first line combined antiretroviral treatment containing either AZT or d4T, which represents approximately 5% of the patients at the Joint Clinical Research Center receiving a AZT or d4T containing treatment. Next generation sequencing (DEEPGEN™HIV) and multiplex oligonucleotide ligation assays (AfriPOLA) were then performed on a subset of patient samples to detect low frequency drug resistant mutations. CD4 cell counts, viral RNA loads, and treatment changes were analyzed in a cohort of treatment success and failures. Over 80% of patients failing first line AZT/d4T-containing cART had predicted drug resistance to 3TC (Lamivudine) and non-nucleoside RT inhibitors (NNRTIs) in the treatment regimen but only 45% had resistance AZT/d4T associated resistance mutations (TAMs). TAMs were however detected at low frequency within the patients HIV quasispecies (1-20%) in 21 of 34 individuals who were failing first-line AZT-containing cART and lacked TAMs by Sanger. Due to lack of TAMs by Sanger, AZT was typically maintained in second-line therapies and these patients had a low frequency of subsequent virologic success. Our findings suggest that continued use of AZT and d4T in first-line treatment in low-to-middle income countries may lead to misdiagnosis of HIV-1 drug resistance and possibly enhance a succession of second- and third-line treatment failures.